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It is documented that people living in malaria endemic areas acquire immunity against malaria after
repeated infections. Studies involving passive transfer of IgG from immune adults to the nonim-
mune subjects have shown that circulating antibodies play an important role, and that immune
adults possess protective antibodies, which susceptible malaria patients do not. Through a differ-
ential immunoscreen, we have identified several novel cDNA clones, which react exclusively and
yet extensively with immune sera samples. Specific antisera raised against the immunoclones inhibit
the growth of parasites in culture. The clones studied so far turn out to be novel conserved Plas-
modium genes. In order to study the response of sera of adults from malaria endemic areas of India
and Africa to these immunogens, we carried out ELISA assays using these immunopeptides, other
P. falciparum specific antigens, peptides, antigens from other infections such as mycobacterial in-
fections and other proteins such as BSA. Children from the same areas and normal healthy urban
people showed very little activity to each of these categories. A large percentage of adults from en-
demic areas responded positively to all the malarial immunogens tested. However, the same per-
sons also showed high response to other antigens and proteins as well. The implications of these
results are reported in this paper.
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Plasmodium falciparum, the causative agent of the
lethal form of malaria, elicits a complex immune re-
sponse.  The parasite exhibits sophisticated mecha-
nisms of immune-evasion and antigenic variation, and
these may be the reasons why, even after a hundred
years of research on malaria, we do not have an effec-
tive malaria vaccine. However, immunity to malaria
does exist. It develops gradually, after many attacks
and over many years, in adults living in highly endemic
areas1. The successful passive transfer of this immuni-
ty by injecting antibodies from malaria immune per-
sons to malaria patients has demonstrated that the
transfer of antibodies alone can trigger protection2–5.
These experiments worked across geographic bor-
ders, as IgG from malaria immune west Africans could
cure east Africans3,4 as well as Thai5 malarial patients.
However, the mechanisms of action, as well as the
molecular specificities of such protective IgG, are not
very clearly established.
Since passive transfer of IgG from immune adults can
cure the patients, the IgG that triggers the curative
process must be present differentially in the immune
sera. Therefore, a differential immunoscreening of an
erythrocytic stage specific cDNA expression library of
P. falciparum was designed and performed in our
laboratory, using malaria immune and acute patient
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sera6. This resulted in the identification of several nov-
el cDNA clones, which reacted exclusively and yet
extensively with immune sera samples6. These coded
for a ribosomal protein P07, epitopes homologous to
SEC65 protein of yeast8, ion-channel protein of influ-
enza virus6, switching antigen of Paramoecium, and
others9. With the availability of the genomic data base,
the molecular properties of the genes are presented in
Table 1. Antisera against most of these epitopes were
found in about 50–60% of sera samples used, show-
ing that it is a combination of such protective IgG
species that may confer protection amongst immune
adults. Most of these protein epitopes are conserved
amongst the Plasmodium species. We have tested
antibodies raised against five of such proteins, and
four of these show inhibition of the growth of P. falci-
parum in culture. We have shown that IgG purified
from antisera raised specifically to PfP0 inhibit the
growth of P. falciparum in culture, as well as protect-
ed mice against challenge with the lethal 17XL variant
of the rodent malarial parasite, P. yoelii10–12. We
have demonstrated that PfP0 protein, in addition to its
ribosomal role, is also present on the surface of mero-
zoites and gametocytes, and constitutes the target for
blocking invasion into red cells11–13.
In order to study whether the B-cell antibody re-
sponse to PfP0, Pf2 and Pf9 epitopes correlated with
the age of the residents in regions other than Orissa,
India, ELISA assays were carried out using sera sam-
ples from Kenya as well. To compare the results with
a standard malaria immunogen, we cloned and ex-
pressed the apical membrane antigen (AMA1) of P.
falciparum. Epidemiological data are presented here.
Material & Methods
Human sera samples : Human blood samples were
collected from various endemic areas of Orissa and
Kenya. Approximately 0.1 to 1.0 ml of blood was
collected using heparanised capillaries or tubes and
the plasma samples were separated and used at a di-
lution of 1 : 200. Appropriate ethical clearances were
taken for such collection.
Synthetic peptides and AMA1 protein used for
ELISA : Synthetic peptides were designed on PfP0
protein based on a hydrophilicity profile. Peptides N1
and N2 represent the amino terminal domain of PfP0,
and C1 and C0 represent the carboxy-terminal do-
mains of PfP011,14. The idea for synthesis of C1 pep-
tide was that, it represents the least conserved domain
of P0 protein across various organisms11. Of the four
peptides representing PfP0, C0 is hydrophobic and it
undergoes into solution only in presence of ~20%
dimethyl sulfoxide. C0 peptide is equivalent to the au-
Table 1. Properties of differential immunoclones
Clone Gene name Southern Predicted protein Protective Surface
name blot expression
Pf 4 PF 11_0313 + Ribosomal protein P0 (Conserved) Yes Yes
Pf 2 PF 13_0027 + Hypothetical 4 TM (Conserved) Yes Yes
Pf 9 Not found + Homologue of Paramecium Yes Yes
surface protein (Conserved)
Pf 1 PF 10_0080 + Put. Endonuclease ND ND
Pf 3 PF 14_0570 + (Conserved) ND ND
Pf 10 PF 14_0737 ND Hypothetical (Conserved) ND ND
Viral ion channel
Homologue (from
cDNA sequence)
ND – Not done.J  VECT  BORNE  DIS  40,  SEPTEMBER & DECEMBER  2003 86
toimmune P-peptide domain15,16, antibodies against
which have been shown to be invasion blocking14. Pf2
and Pf9 peptides were also designed based on their
hydrophilicity and immunogenic properties6,9. The se-
quences of all the peptide antigens used for ELISA
are given below.
N1 – DNVGSNQMASVRKSLR (16 residues)
N2 – SVRKSLRGKATILMGKNT (18 residues)
C1 – AKADEPKKEEAKKVE (15 residues)
C0 – EEEEEEDGFMGFGMFD (16 residues)
Pf 2 – KLMNIKFFEDKNIKLGKC (18 residues)
Pf 9 – RTCLDAAWTTDKMCS (15 residues)
Another potential malaria vaccine candidate is apical
merozoite antigen 1 (AMA1)17. A ~35 kDa expres-
sion protein from the extreme carboxy terminal do-
main of P. falciparum AMA1 was also used as an
antigen for ELISA. This protein was expressed as
HIS-tagged protein in pQE30 vector (Savithri et al—
unpublished data).
ELISA : 96 well (Nunc, Maxisorp) plates were coat-
ed with 100 ng of peptide antigens and 200 ng of
AMA1 protein in a total volume of 100 µl. Antigens
were coated overnight at 4oC. The plates were then
blocked with 5% milk in PBS for 1 hr at 37oC. Plates
were washed with PBST (PBS containing 0.05%
Tween-20) and probed with human sera at a dilu-
tion of 1 : 200 in PBS. The antibody binding was al-
lowed to take place at 37oC for 2 h. The plates were
washed extensively with PBST and then probed with
secondary anti-human antibodies (Boehringer Man-
nheim) at a dilution of 1 : 2000 in PBS. The second-
ary antibody binding was carried out at 37oC for 1 h
and the plates were then extensively washed with
PBST. The reaction was developed using ABTS
(Boehringer Mannheim) for 10 min and the absor-
bance was measured at 405 nm in an ELISA reader
(EL808, Biotek Instruments). All the samples were
screened in duplicates and the readings repres-
ent the geometric mean of the two values. Proper
positive and negative controls were also included in
each plate.
Results & Discussion
Although PfP0 protein has been expressed as a re-
combinant GST fusion protein, it was not possible to
use this for the ELISA assay, as GST alone gave a
very high reactivity with most human sera samples.
Thus it was decided to use various synthetic peptides
to assess the antibody reactivity of the samples. PfP0
was represented with four peptides; N1 and N2 rep-
resenting the amino terminal domain, and C1 and C0
representing the carboxy-terminal domains. Pf 2 and
Pf9 peptides were used for these two antigens. The
carboxy-terminal 250 amino acid domain of AMA1
was used as a HIS-tag fusion protein.
Fig. 1 shows the ELISA assays with serum samples
from Orissa, while Fig. 2 shows the results with serum
samples from Kenya. It is clear that the response of
adults is much higher as compared to that of children
for each of the peptide antigens used. This is consis-
tent with our differential screen, which had used im-
mune versus susceptible sera for screening. These re-
sults also show that the reactivity of these peptide an-
tigens with sera from immune adults is also observed
in Kenya and Africa, and is not a peculiarity of Orissa
in India. Thus, the reactivity of these samples showed
that immune response is generated against these
epitopes in Africa as well as in India. It was observed
that the same immune serum samples reacted with the
peptides, although the cut-off parameters predicted
different frequencies of reactivities for different
epitopes. It has been shown that none of these pep-
tides are cross-reactive and that these are distinct an-
tigens on P. falciparum. Irrelevant peptides such as
transcription factors and RNase1 also showed similar
patterns of activity, although the reactivity was much
lower (Fig. 3). Such data suggest that the immune re-
sponsiveness is a state attained by the immune adults,
and that there is a general polyclonal activation achie-
ved against several parasite determinants in the im-
mune adults. Hypergammaglobulinimia has been re-
ported earlier for such persons2. However, the reac-
tivity against AMA1 protein did not fit that pattern,
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Fig. 1: ELISA analysis histogram of 60 and 40 sera samples from adults (>12 years) and children (< 12 years) respec-
tively, residing in the Keonjhar district of Orissa for the three peptides N1, N2 and C1 of the PfP0 protein.
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Fig. 2: ELISA analysis of 47 sera samples from adults (>12 years) as well as children (<12 years), re-
siding in the Msambweni district of Kenya for the five peptides; N1, N2 and C1 of the PfP0
protein; Pf2 and Pf9 peptides. Y-axis— OD405 value
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Fig. 3: ELISA analysis of sera samples from adults (>12 years) and children (<12 years) residing in the Keonjhar dis-
trict of Orissa, India and the Msambweni district of Kenya for the peptides and antigens. Antigens used
were : N1 and PfP0-C0 peptides of the PfP0 protein; HuP0-C0 : the equivalent C0 peptide of the human P0
protein; Pf9 peptide; BCG; TB : a surface antigen from Mycobacterium tuberculosis; RNase, and AMA1-C :
AMA1-carboxyterminal domain protein. Y-axis— OD405 value
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compared to adults from these malaria endemic areas
(Fig. 3). Longitudinal study of natural immune re-
sponses to AMA1 has been carried out in several ho-
loendemic regions of Africa, and different domains of
AMA1 appear to react differently17–19. Invasion
blocking antibodies to the amino-terminal domain of
AMA1 has been reported19, but the response to the
carboxy-terminal domain is as yet unreported. From
our results it appears as though the response to the
carboxy-terminal domain is restricted in immune
adults.
It is observed that parasites protect themselves from
host immune responses by using proteins that mimic
host cells. The ribosomal protein P0 itself is closer to
the mammalian counterpart, as compared to other
protozoan species7. Other malaria epitopes that are
established to be crucial for hepatocyte and red cell
invasion (TRAP and MSP1) are also related to host
motifs (thrombospondin and epidermal growth factor
(EGF-like folds). Chronic malaria is known to gener-
ate antibodies that cross-react with host red cells and
other host-proteins. However, it is also documented
that persons living in malaria endemic areas suffer less
with autoimmune disorders than people in malaria free
areas20. How can we explain this?
It is envisaged that the protective IgG present in the
malaria immune adults can only limit the parasites, and
not clear the parasitaemia completely. The protective
immune response is hypothesised to be dependent on
the presence of small sub-clinical levels of para-
site21,22.  Indeed, such naturally acquired immunity is
lost if the subject moves out of endemic areas, and
thus the exposure to pathogen is lost. The establish-
ment of a host-parasite interaction such that the host is
clinically normal, and the parasite is also transmitted, is
an equilibrium situation normally favoured in evolution.
This state arises when there is enough immune re-
sponse to control the levels of parasitaemia. It is
known that malarial parasite generates immune eva-
sive ‘smoke-screen epitopes’ to keep the host im-
mune response busy23. The immune response against
such smoke-screen epitopes may not control the par-
asite levels effectively. An effective control occurs only
when immune responses against crucial epitopes are
generated. Since the crucial epitopes are essentially
mimics of the host, we start seeing the auto-reactivity.
However, the presence of the parasite appears to limit
such immune response. Elegant models have been pro-
posed indicating a feedback mechanism, such that if the
parasite level falls below a certain limit, the ‘effective im-
mune response’ gets turned off 21.  Even though mole-
cules such as TNF and NO have been implicated in
such a process20, the actual mechanism(s) is (are) not
yet understood. In order to use the naturally acquired
immunity to malaria for the purpose of a vaccine, we
need to understand these close interactions between
parasites and host immune cells.
References
1. Baird JK. Host age as a determinant of naturally acquired
immunity to Plasmodium falciparum.  Parasitol Today
1995; 11 : 105–11.
2. Cohen S, McGregor IA, Carrington  SP.  Gammaglobulin
and acquired immunity to human malaria. Nature 1961;
192 : 733–7.
3. McGregor IA, Carrington SP, Cohen S. Treatment of east
African P. falciparum malaria with west African human
gamma-globulin. Trans R Soc Trop Med Hyg 1963; 57 :
170–5.
4. Edozien JC, Gilles HM, Udeozo IOK. Adult and cord-
blood gamma-globulin and immunity to malaria in Nigeri-
ans. Lancet 1962; ii : 951–5.
5. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druihle P.
Mechanisms underlying the monocyte-mediated anti-
body-dependent killing of Plasmodium falciparum asex-
ual blood stages. J Exp Med 1995; 182 : 409–18.
6. Lobo CA, Kar SK, Ravindran B, Kabilan L,  Sharma S.
Novel proteins of Plasmodium falciparum identified by
differntial immunoscreening using immune and patient
sera. Infect Immun 1994; 62 : 651–6.
7. Goswami A, Chatterjee S, Sharma S. Cloning of a ribsom-
al phosphoprotein P0 gene homologus from P. falci-
parum. Mol Biochem Parasitol 1996;  82 : 117–20.
8. Goswami A, Sharma S. A differential clone of Plasmodi-
um falciparum shows homology to the yeast SEC65 do-
mains. J Parasit Dis 1996; 20 : 133–6.
9. Singh NJ, Sehgal A, Sharma S. Characterisation of a dif-
ferential immunoscreen epitope of Plasmodium falci-MANNAN et al :  IMMUNE RESPONSE TO MALARIA 91
parum using combinational agents. Parasit Immunol
2000; 22 : 333–40.
10. Goswami A, Singh S, Redkar VD, Sharma S. Characterisa-
tion of P0, a ribosomal phosphoprotein of Plasmodium
falciparum. J Biol Chem  1997; 272 : 12138–43.
11. Chatterjee S, Singh S, Sohoni R, Kattige V, Deshpande C,
Chiplunkar S, Kumar N, Sharma S. Characterisation of do-
mains of the phosphoriboprotein P0 of Plasmodium fal-
ciparum. Mol Biochem Parasitol 2000; 107 : 143–54.
12. Chatterjee S, Singh S, Sohoni R, Singh NJ, Vaidya A,
Long C, Sharma S. Antibodies against ribosomal phos-
phoprotein P0 of Plasmodium falciparum protect mice
against challenge with Plasmodium yoelii. Infect Immun
2000;  68 : 4312–8.
13. Singh S,  Sehgal A, Waghmare S,  Chakraborty T,  Gos-
wami A,  Sharma S. Surface expression of the conserved
ribosomal protein P0 on parasite and other cells.  Mol
Biochem Parasitol 2002; 119 : 121–4.
14. Singh S, Chatterjee S, Sohoni R, Badakare S, Sharma S.
Sera from lupus patients inhibit growth of Plasmodium
falciparum in culture.  Autoimmunity 2001; 33 : 253–63.
15. Koren E, Reichlin MW, Kosec M, Fugate RD, Reichlin M.
Autoantibodies to the ribosomal P proteins react with a
plasma membrane-related target on human cells.  J Clin
Invest 1992; 89 : 1236–41.
16. Hirohata S, Nakanishi K. Antiribosomal P protein antibody
in human systemic lupus erythematosus reacts specifically
with activated T cells. Lupus 2001; 10 : 612–21.
17. Thomas  AW, Trape  JF, Rogier  C, Goncalves  A, Rosario
VE, Narum DL. High prevalence of natural antibodies
against P. falciparum 83-kilodalton apical membrane anti-
gen (Pf83/AMA-1) as detected by capture-enzyme-linked
immunosorbent assay using full-length baculovirus re-
combinant Pf83/AMA-1.  American J Trop Med Hyg,
1994; 51 : 730–40.
18. Udhayakumar V, Kariuki S, Kolczack M, Girma M, Rob-
erts JM, Oloo AJ, Nahlen BL, Lal AA.  Longitudinal study
of natural immune responses to the P. falciparum apical
membrane antigen (AMA-1) in a holoendemic region of
malaria in Western Kenya : a Asembo Bay Cohort Project
VIII. American J Trop Med Hyg 2001; 65 : 100–7.
19. Hodder AN, Crewther PE, Anders RF. Specificity of the
protective antibody response to apical membrane antigen-
1.  Infect Immun 2001; 69 : 3286–94.
20. Daniel-Ribeiro CT. Is there a role for autoimmunity in
immune protection against malaria? Mem Inst Oswaldo
Cruz 2000; 95 : 199–207.
21. Perignon J, Druilhe P. Immune mechanisms underlying the
premunition against Plasmodium falciparum malaria. Mem
Inst Oswaldo Cruz 1994; 89 : 51–3.
22. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C,
Bryden M, Cloonan N, Anderson K, Mahakunkijcharoen
Y, Martin LB, Wilson D, Elliott Salenna, Elliott Suzanne,
Eisen DP, Weinberg JB, Saul A, Good MF.  Immunity to
malaria after administration of ultra-low dosage of red cells
infected with Plasmodium falciparum.  Lancet 2002; 360 :
610–7.
23. Anders RF. Multiple cross-reactivities amongst antigens
of Plasmodium falciparum impair the development of
protective immunity against malaria. Parasite Immunol
1986; 8 : 529–39.